WHO WE ARE

A consortium of key players in breast cancer clinical research in Québec

RESEARCH THAT CARES

The benefits of treatment options
available through clinical research

PROGRAMME ACCÈS-RECHERCHE
DR ANDRÉ-ROBIDOUX

Bringing clinical research closer to patients

Together, we have been personally involved for many years to bring together the major players in clinical research in Québec. Our vision was that the fight against breast cancer would require increasing access and participation in innovative research trials. Supported by a private contribution from our family, the McPeak-Sirois Group became in 2015 a reality of which we are particularly proud. It is today one of the most important consortiums in breast cancer clinical research in Canada.

Susan McPeak and Charles Sirois

Together, we have been personally involved for many years to bring together the major players in clinical research in Québec. Our vision was that the fight against breast cancer would require increasing access and participation in innovative research trials. Supported by a private contribution from our family, the McPeak-Sirois Group became in 2015 a reality of which we are particularly proud. It is today one of the most important consortiums in breast cancer clinical research in Canada.

Susan McPeak and Charles Sirois

Our mission is to fight breast cancer
more effectively by increasing
patients’ access and participation
to clinical trials

Objective 2023

The Programme Accès-recherche Dr André-Robidoux was created to bring clinical research closer to breast cancer patients throughout Quebec by developing a partnership with at least one establishment per region by 2023.

As of Fall 2021, six hospital centers had joined the four founding institutions of the Group through its Programme Accès-recherche Dr André-Robidoux, namely the CIUSSS de l’Est-de-l’Île-de-Montréal - Hôpital Maisonneuve-Rosemont (April 2017), CIUSSS de l’Estrie – Centre hospitalier universitaire de Sherbrooke (May 2018), Montreal West Island CIUSSS – St-Mary's Hospital (July 2019), CISSS de la Montérégie-Centre - Hôpital Charles-Le Moyne (March 2020), CIUSSS du Saguenay-Lac-St-Jean - Hôpital de Chicoutimi (March 2020) and CIUSSS du Nord-de-l'Île-de-Montréal – Hôpital du Sacré-Cœur-de-Montréal (July 2021).

"Participating in the Group will allow us to have access to new clinical trials, which means additional research for the benefit of patients in our region" Dr. Michel Pavic, Oncologist and Head of service, CIUSSS de l’Estrie-CHUS.

STATISTICS ON CLINICAL RESEARCH
88 %

Cancer survival rate after 5 years. This encouraging rate is attributable in part to treatments available through clinical research.

44 %

Percentage of all breast cancer clinical trials conducted in Canada that are available in Quebec hospitals (about 100). There are 3200 clinical trials worldwide.

4,5 %

Average participation rate of cancer patients in clinical trials in Canada. The goal of the Group is to reach or exceed the target participation of 10% set by the American Society of Clinical Oncology for breast cancer patients.

NEWS
The McPeak-Sirois Group reiterates how important it is for everyone affected by breast cancer to have access to clinical research, regardless of where they live [...]
The team at McPeak-Sirois Group is pleased to announce the launch of the website of the first Metastatic Breast Cancer Registry in Quebec; it will allow researchers to make requests for data analysis [...]
FOUNDING MEMBERS